Trials / Completed
CompletedNCT00538811
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Aga Khan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | interferon alpha-2b, ribavirin, interferon-gamma, | |
| DRUG | interferon alpha-2b, ribavirin, amantadine |
Timeline
- First posted
- 2007-10-03
- Last updated
- 2010-10-27
Locations
2 sites across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT00538811. Inclusion in this directory is not an endorsement.